NOVALIQ-GMBH
24.4.2018 17:55:11 CEST | Business Wire | Press release
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3).
The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma.
Scientific posters supported by Novaliq will include:
- “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schmidl D., Werkmeister R., Adzhemian N., Kosobokovs S., Krösser S., Schmetterer L. Poster presentation on Sunday, April 29, 3:15-5:00 PM; Poster Board: B0119
- “Ocular and Systemic Distribution of 14 C- Perfluorohexyloctane following Topical Ocular Administration to Rabbits.” Authors: Krösser S., Spencer E., Grillenberger R., Struble C., Eickhoff K. Poster presentation on Tuesday, May 1, 8:15-10:00 AM; Poster Board: A0383
- “Evaluating the lubricating effect of semifluorinated alkanes on the ocular surface.” Authors: Agarwal P., Khun D., Krösser S., Eickhoff K., Wells F. S., Willmott G. R., Craig J. P., Rupenthal I. D. Poster presentation on Tuesday, May 1, 11:15-13:00 AM; Poster Board: C0076
- “The pharmacodynamic effect of LatanoSol eye drops on IOP of normotensive dogs.” Authors: Eickhoff K., Prusakiewicz J., Uhlmann L., Struble C., Löscher F., Krösser S. Poster presentation on Tuesday, May 1, 8:15-10:00 AM; Poster Board: B0037
“We are proud to share and discuss the scientific data on our innovative and water-free platform technology with researchers, clinicians, and industry,” said Sonja Krösser, PhD, VP Preclinical and Clinical Development, Novaliq. “Our dedication to science is the basis for advancing our unique pipeline and developing innovative products that help physicians better serve their patients.”
The Novaliq team will be available at ARVO 2018 in Honolulu, HI to discuss the research and to answer questions. To arrange a meeting, please send an email to event@novaliq.com with day and time preference.
About Novaliq – Founded in 2007, Novaliq GmbH is a Heidelberg-based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases, including dry eye through preservative-free and multi-dose formulations. Novaliq has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. The company’s most advanced products are NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe, and NovaTears®+Omega-3, which was just recently CE-approved in Europe. CyclASol®, a second-generation prescription drug, is currently in pivotal phase of clinical development. More on www.novaliq.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180424006177/en/
Contact:
For US:
Michele Gray, + 1 (917) 449-9250
Principal, Gray
Communications, LLC.
michele_gray@me.com
or
For
EU/Asia:
Heidrun Kirsch, + 49 6221 50259 243
VP Marketing
hkirsch@novaliq.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egon Zehnder Elects German Herrera as New Chair28.1.2026 20:01:00 CET | Press release
Herrera succeeds Michael Ensser, who will remain an active member of the Firm after his term in a planned transition. Egon Zehnder, the world’s premier leadership advisory firm, today announced that, in accordance with its established governance and three-year election cycle, German Herrera has been elected as the Firm’s next Chair by its worldwide partnership. Herrera will assume the role effective March 1, 2026. He will succeed Michael Ensser, who has held the position since 2022, in a planned succession at the conclusion of his regular term. Herrera joined the Firm in 1998 in Bogotá and has helped shape the Firm’s global presence, taking on a broad range of leadership roles, from co-leading the Global Family Business Advisory Practice to serving on the Executive Committee and the Market Council. Most recently, Herrera has guided Egon Zehnder’s U.S. market through a period of impressive growth and transformation, which today includes 15 offices and more than 150 consultants. As the f
De' Longhi Group - Record Preliminary 2025 Revenues of €3.8 Billion, up 10.4% at Constant Exchange Rates28.1.2026 19:25:00 CET | Press release
The Group closed 2025 with brilliant results and solid growth at constant currency across both divisions throughout the year, further confirmed by an organic expansion of 8.2% in Q4 Below are the preliminary 2025 revenues for the De’ Longhi S.p.A. Group: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128191504/en/12 months, revenues at € 3,801.5 million, growing at 8.7% (+10.4% at constant currency); fourth quarter, revenues at € 1,340.0 million, growing at 5.7% (+8.2% at constant currency). Fabio de' Longhi, CEO of the Group, stated: "The Group achieved solid growth at constant currency of 10.4% in 2025, characterized by consistent results throughout the year. We are particularly pleased with the excellent performance achieved in the fourth quarter, which successfully overcame the challenges posed by the current market environment. The household division consolidated its recent growth momentum during the quarter, with or
Organon Completes Divestiture of JADA® System to Laborie28.1.2026 18:45:00 CET | Press release
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp. Please see our prior announcement for a summary of the transaction terms. Indications for Use The JADA® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Contraindications Ongoing intrauterine pregnancy Untreated uterine rupture Unresolved uterine inversion Current cervical cancer Known uterine anomaly Current purulent infection of vagina, cervix, or uterus For C-sections: Cervix <3 cm dilated before use of JADA Warnings Avoid excessive force when inserting JADA into the uterus or trauma to uterine wall may occur, including perforation. The safety and effectiveness of the JADA System in delivery at a gestational age <34 weeks or, if multiples, uter
Laserfiche Expands AI Data Capture with Auto-Classification to Transform Data into Business Intelligence28.1.2026 16:00:00 CET | Press release
New intelligent features automatically organize and classify documents, transforming how organizations manage information at scale. Laserfiche — the leading SaaS provider of intelligent content management — today announced major enhancements to its AI-powered data extraction tool, Smart Fields. The update introduces automated document classification and tagging, allowing organizations to move from unstructured content to informed decisions in seconds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128228490/en/ Using natural language prompts instead of rigid, ruled-based OCR, Smart Fields can now identify document type — such as invoices, taxpayer identification forms, or student transcripts — and automatically apply the correct metadata template using AI. Users can also use Smart Fields to automatically add informational and security tags to files that meet certain criteria, defined using a natural language prompt. Users
Intersolar Africa 2026 to Position Nairobi as East Africa’s Key Hub for Solar and Energy Storage28.1.2026 15:20:00 CET | Press release
East Africa is emerging as one of the world’s most dynamic regions for solar power and battery storage. On 3–4 February 2026, Intersolar Africa will take place at the Sarit Expo Centre in Nairobi, expanding from the successful Intersolar Summit Africa in 2025 into a full international exhibition and conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128955267/en/ Intersolar Africa will take place on February 3-4 in Nairobi. East Africa’s Energy Market and Opportunities Rapid population growth, industrialization, and rising electricity demand are putting pressure on power systems across East Africa. Limited generation capacity, grid instability, and high electricity costs constrain economic growth. Solar photovoltaics combined with energy storage have emerged as the most cost-effective and scalable solution to expand capacity, stabilize supply, and strengthen long-term energy security for businesses and communities
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom